ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / AZN / insiders
NVS (66) MRK (75) ABT (77) NVO (57) ⌘ Pro Terminal β†’

AstraZeneca PLC (AZN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$186.65 +7.02% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $188.65

AstraZeneca PLC (AZN) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

πŸ“Š Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) β†’
ROARABLE C β€’ HOLD / WATCH Cap $270.45B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AZN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, AstraZeneca PLC (NYSE: AZN) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $186.65 (+7.02% 1D, market cap $270.45B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, AZN ranks #154 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does AZN compare to NVS and MRK in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C (62/100 RQD), trailing P/E of 32.8x, gross margin of β€”, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $307.40B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AZN?
β–Ό

For AstraZeneca PLC (AZN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #154 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $188.65 (+1.07%)🧬 Cannibal Buyback (-1.24% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 15.8% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY β€’ 54.3% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C
025507510062
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C Β· Rk C
Cash (12)Whales (13)SEC (16)Macro (9)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
$224 Bull$190 Base$148 Bear
πŸ“¬ FREE AZN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for AZN)Realized 20D OHLCV Swing Band: Β±4.3%
Deterministic 5-Pillar Attribution (62/100 Composite)
πŸ” WHY AZN SCORES 62/100 (C) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–² #2 Bullish Driver: Whale & Options Positioning+13/20 pts (21% of score)

20D Institutional Volume Accumulation (Β±4.3% realized swing band)

β–Ό #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (56.8) create a -11 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
54
Grade C-$155.82+8.3% Next Q
Q2 (-2Q)
57
Grade C$168.82+0.7% Next Q
Q3 (-1Q)
59
Grade C$170.08+9.7% Next Q
Current
62
Grade C$186.65+0.7% Hist 90D Ξ±
Trajectory: C- (54) β†’ C (62)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the AZN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 62/100 (C) score, AZN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) β€” any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($164.80) or 200D SMA ($180.02) invalidates the momentum regime and cuts Target Base ($190.01) toward Bear Floor ($148.21).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AZNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAZN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

AZN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AZN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AZN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (AZN Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
AZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.74%⚑ TESTING RESISTANCE
2026-11-02O $169.5H $186.7L $169.5C $186.7VOL 3.72M
RES: $188.8SUP: $154.2SMA50: $164.8SMA200: $180.0
$199.4$187.0$174.5$162.0$149.5RES $188.8SUP $154.2$186.72026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ AZN Butterfly Map β†’ + Track AZN β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth

vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AZN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for AZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AZN)

Health Care Rank #154 of 1016 βš”οΈ NVS vs AZN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (AZN vs. NVS, MRK, ABT, NVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AstraZeneca PLC (AZN) ranks #154 by composite RQD confidence (62/100, grade C) and #8 by equity capitalization ($270.45B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while MRK leads on capital efficiency and profitability with 20.7% ROIC and 74.8% gross margin. ABT currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with AZN at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AZN ACTIVE
AstraZeneca PLC
C 62/100 32.8x β€” 9.9% +7.02% $270.45B Benchmark Subject
NVS
Novartis AG
C+ 66/100 32.8x β€” 9.9% -0.19% $307.40B /nvs-vs-azn β†’
MRK
Merck & Company Inc.
B 75/100 19.8x 74.8% 20.7% +2.18% $361.02B /mrk-vs-azn β†’
ABT
Abbott Laboratories
B+ 77/100 27.7x 56.4% 11.9% +1.56% $180.95B /abt-vs-azn β†’
NVO
Novo Nordisk A/S
D+ 57/100 32.8x β€” 9.9% +2.20% $173.31B /nvo-vs-azn β†’

2. AZN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

AstraZeneca PLC (AZN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $270.45B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of β€”, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. AZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, AstraZeneca PLC (NYSE: AZN) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $186.65 (+7.02% 1D, market cap $270.45B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, AZN ranks #154 in composite RQD confidence.

How does AZN compare to NVS and MRK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C (62/100 RQD), trailing P/E of 32.8x, gross margin of β€”, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $307.40B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AZN?

For AstraZeneca PLC (AZN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #154 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AZN trading relative to its 50-day, 200-day, and 52-week technical levels?

AZN last traded at $186.65 (+7.02% on volume of 5,465,719 shares), positioning the stock +13.26% above its 50-day simple moving average ($164.80) and +3.68% above its 200-day simple moving average ($180.02). Across its 52-week range of $153.41 to $212.71, AZN sits at the 56.1% percentile with a 14-day RSI of 56.8 (BULLISH MOMENTUM) and an implied next-earnings move of Β±4.3% ($178.62 to $194.68).

AZN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are AZN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies AZN leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: AZN RQD Cockpit AZN 12M Forecast AZN Earnings & Move AZN Dividends & DRIP AZN Insiders & 13F AZN Whale Options AZN Profit Sankey AZN News & Why
ROARABLE RATING BRIEF β€’ RQD 62/100 (C) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

AZN β€” AstraZeneca PLC: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:07:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AZN scores 62 out of 100, grade C, labeled "Roarable Hold β€” Fair / Balanced Risk-Reward." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. Per the RQD rating, this pillar reflects ROIC of 9.9% and an FCF yield of 2.21%. Returns on capital are positive but the free-cash-flow yield is thin, meaning the market is pricing in substantial future growth relative to current cash generation.
  • Whale 13F Flow: 13 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score is moderately constructive, though the underlying flow detail is not itemized in the source data.
  • Insider Conviction: 12 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is middling, indicating no strong directional insider signal in either direction.
  • Macro Regime Fit: 9 / 20. Per the RQD rating, this pillar reflects a beta of 0.91 and sector sensitivity. This is the weakest pillar, suggesting the stock's risk profile is not especially well aligned with the current macro regime as scored.
  • Forensic Balance Sheet: 16 / 20. Per the RQD rating, this pillar reflects an Altman Z of 3.74, Piotroski F of 8/9, and Debt/Equity of 0.39. This is the strongest pillar and signals low balance-sheet risk.

For a prospective investor, the upside case rests on balance-sheet durability and steady institutional interest, while valuation is the principal tradeoff: per the market data, trailing P/E is 32.8 and forward P/E is 27.6, with a 2.21% FCF yield. The low macro-fit score and the modest insider signal argue for treating this as a balanced rather than high-conviction setup. This is an educational reading of the scores, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
174.4$270.45B32.827.6215.310%0.91$153.41 - $212.719.9%

Business

Per the profile section, AstraZeneca PLC is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, operating margin is 13.9% and net margin is 10.9%. Not available in source data for product lines, customer segments, or specific revenue-generation mechanics.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section:

  • Yahoo Finance (MARKET WIRE, YELLOW): "Is AstraZeneca (AZN) Stock Cheap?" β€” a valuation-framing piece with no specific figures in the source summary.
  • Reuters (CATALYST, GREEN): "AstraZeneca CEO strikes bullish tone on pipeline as stock rallies" β€” the most constructive item, tied to pipeline commentary.
  • Benzinga (MARKET WIRE, YELLOW): "Why Is AstraZeneca Stock Trading Higher Today?" β€” a short-term price-move explanation.
  • Yahoo Finance (MARKET WIRE, YELLOW): "AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings" β€” an earnings-based valuation framing.
  • TradingKey (MARKET WIRE, YELLOW): "AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14" β€” a historical price-move recap.
  • Stocktwits (CATALYST, GREEN): "BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal" β€” per this item, a partner-related trial missed its endpoint, while BBIO itself rose sharply; the item is flagged as a catalyst on the AZN-related feed.

Risk watch items: the Stocktwits headline describes a heart-drug trial miss involving AstraZeneca and Ionis, which bears on pipeline expectations. Butterfly signals: per the Butterfly Supply-Chain Graph, there are no links and no proprietary signals.

Open Questions

  • What are the reported revenue, operating income, net income, and free-cash-flow figures by period? (Financials section is NONE.)
  • What is the analyst consensus rating and price target distribution? (Analyst data is NONE.)
  • Who are the institutional and insider holders, and what are their recent 13F and Form 4 transactions? (Holders data is NONE.)
  • What is the magnitude and timing of the Ionis-partnered heart-drug trial miss on AstraZeneca's pipeline and valuation?
  • What drives the gross margin figure of 0%, and is it a data artifact or a real reporting gap?

AZN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AstraZeneca PLC (AZN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to AZN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AZN Bull vs. Bear Conversation Board β€” What's Your Call at $186.65?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AZN 🐻 50% BEARISH CONVICTION
1. Pick Your Side on AZN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $188.35 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is AZN (C β€’ RQD 62/100) a Buy at $174.40?

Welcome to the AZN (AstraZeneca PLC) Roar Pit. Current RQD Composite is 62/100 (Roarable Hold β€” Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $132.54 (-24.0%)
Spot @ $174.40

Pump the brakes on AZN β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AZN, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless AstraZeneca PLC expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $221.49 (+27.0%)
Spot @ $174.40

AZN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AZN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $174.40 (52-wk range $153.41 - $212.71), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%